Verona Pharma (VRP)

 

VRP Share PerformanceMore

52 week high210.00 24/10/16
52 week low120.75 17/02/17
52 week change -21.00 (-13.55%)
4 week volume294,016 28/03/17

Media for (VRP)

Presenter: Jan-Anders Karlsson
28/07/2014

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Global Offering and Application to List on NASDAQ

RNS Number: 6578C Verona Pharma PLC 19 April 2017 THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION (EU) NO 596/2014 Verona Pharma Announces Launch of Global Offering and Application to List on the NASDAQ Global Market 19 April 2017, London - Verona Pharma plc (AIM: V...

FDA authorises start of Verona Pharma's US trial

Verona Pharma announced the US Food and Drug Administration (FDA) authorized the initiation of a pharmacokinetic ...

FDA Authorisation to Proceed RPL554 Investigation

RNS Number: 5435C Verona Pharma PLC 18 April 2017 THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION (EU) NO 596/2014. Verona Pharma Receives Authorization from the U.S. FDA to Proceed with Clinical Investigation of RPL554 with the Acceptance of Investigational New Drug Applic...

All resolutions passed at Verona AGM

Verona Pharma has confirmed that all resolutions proposed at the Annual General Meeting (AGM) held today were duly ...

Result of AGM

RNS Number: 3537C Verona Pharma PLC 12 April 2017 Verona Pharma plc ("Verona Pharma" or the "Company") Result of AGM 12 April 2017, London -Verona Pharma plc (AIM: VRP.L), a clinical-stage biopharmaceutical company focused on developing and commercialising innovative therapeutics for the treatment of respiratory diseases, announces that all reso...

Files Statement for Proposed Global Offering

RNS Number: 4837B Verona Pharma PLC 04 April 2017 FOR RNS RELEASE: THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION (EU) NO 596/2014 Verona Pharma Files Registration Statement for Proposed Global Offering 4 April, 2017, London - Verona Pharma plc (AIM: VRP.L) ("Verona...

Files Statement for Proposed Global Offering

RNS Number: 4464B Verona Pharma PLC 04 April 2017 FOR RNS RELEASE: THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION (EU) NO 596/2014 Verona Pharma Files Registration Statement for Proposed Global Offering 3 April, 2017, London - Verona Pharma plc (AIM: VRP.L) ("Verona...

1st Patient Dosed in Ph2a Trial for RPL554 in CF

RNS Number: 4276B Verona Pharma PLC 04 April 2017 THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION (EU) NO 596/2014. Verona Pharma Doses First Patient in Phase 2a Clinical Trial Evaluating RPL554 for Cystic Fibrosis 4 April 2017, London-Verona Pharma plc (AIM: VRP.L), a clinic...

Fundamental DataMore

EPS-0.74
Dividend yield0 %

Equity Research (VRP)

edison investment research
Verona Pharma plc
26/07/2016
Verona’s £44.7m gross raise removes funding uncertainty, allowing the company to focus on the clinical progress of its respiratory asset RPL554, a dual PDE3/PDE4 inhibitor. RPL554 is in development...
hardman & co
Verona Pharma plc
20/06/2016
VRP is developing first-in-class drugs to treat unmet medical needs in respiratory disease. Over the last two years’ VRP has reported positive outcomes from a five stage Phase I/IIa programme which...
hardman & co
Verona Pharma plc
16/03/2016
VRP is developing first-in-class drugs that treat unmet medical needs in respiratory disease. RPL554 is being fast-tracked to commercialisation by focusing on a $3.2bn market segment poorly serviced...

Latest discussion posts More

  • Re: SEC Filing

    Mol. What is your take on all this. Is it a strong positive for the company in terms of positioning them in the US or is it just a major dilution for us long suffering uk ...
    22-Apr-2017
    millwallfan
  • Re: SEC Filing

    We are offering 44,481,617 of our ordinary shares in a global offering. We are offering 4,448,162 American Depositary Shares, or ADSs, through the underwriters named in this ...
    22-Apr-2017
    mol42
  • RNS Nasdaq

    Further to rns today bit more detail here http://www.nasdaq.com/article/respiratory-biotech-verona-pharma-sets-terms-for-75-million-us-ipo-cm775580 mol
    19-Apr-2017
    mol42

Users' HoldingsMore

Users who hold Verona Pharma also hold..
LLOYDS GRP.19%
GULF KEYSTONE11%
RANGE RES.11%
BP10%
SIRIUS MINERALS10%

Codes & Symbols

ISINGB00BYW2KH80
SymbolsVRP, LSE:VRP, VRP.L, VRP:LN, LON:VRP, XLON:VRP